Skip to main content

Kariv Tomer's Form 4 filing

Keros Therapeutics, Inc. (KROS) · filed Oct 17, 2025

Accession no.
0000921895-25-002765
Filed
Oct 17, 2025, 5:53 PM ET
Trade date
Oct 15, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions. Open-market sales total $85.0M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kariv TomerCIK 0001568077Director, 10% Owner
Nussbaum RanCIK 0001609805Director, 10% Owner
Pontifax (Cayman) IV L.P.CIK 000172602910% Owner
Pontifax (China) IV L.P.CIK 000172603010% Owner
Pontifax (Israel) IV, L.P.CIK 000172603910% Owner
Pontifax Management 4 G.P. (2015) Ltd.CIK 000172633410% Owner
Pontifax Late Stage Fund L.P.CIK 000179376910% Owner
Pontifax Late Stage GP Ltd.CIK 000179377010% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 15, 2025Common Stock, $0.0001 par value per shareSSaleDisposed−2,284,612$17.75−$40,551,8630Indirect
Oct 15, 2025Common Stock, $0.0001 par value per shareSSaleDisposed−1,121,045$17.75−$19,898,548.750Indirect
Oct 15, 2025Common Stock, $0.0001 par value per shareSSaleDisposed−1,226,412$17.75−$21,768,8130Indirect
Oct 15, 2025Common Stock, $0.0001 par value per shareSSaleDisposed−155,262$17.75−$2,755,900.50Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)